8-K: Bristol Myers Squibb Reports Strong Growth Portfolio, Raises Dividend

Bristol Myers Squibb announced its Q4 and full-year 2025 financial results, showcasing robust growth in its new product portfolio despite declines in legacy assets, and provided optimistic 2026 guidance.

Summary

• Total revenues for Q4 2025 increased 1% to $12.5 billion, while full-year revenues were $48.2 billion, relatively flat compared to 2024.
• The Growth Portfolio revenues surged 16% in Q4 to $7.4 billion and 17% for the full year to $26.4 billion, driven by immuno-oncology, Camzyos, Breyanzi, and Reblozyl.
• The Legacy Portfolio revenues decreased 15% in Q4 to $5.1 billion and 15% for the full year to $21.8 billion, primarily due to generic impacts on products like Revlimid, Pomalyst/Imnovid, Sprycel, and Abraxane.
• GAAP EPS for Q4 2025 was $0.53, and non-GAAP EPS was $1.26, both including a net impact of $(0.60) from Acquired IPRD charges and licensing income.
• Full-year GAAP EPS was $3.46, and non-GAAP EPS was $6.15, both including a net impact of $(1.40) from Acquired IPRD charges and licensing income.
• The company provided 2026 guidance, projecting total revenues of approximately $46.0 billion to $47.5 billion and non-GAAP EPS in the range of $6.05 to $6.35.
• The quarterly dividend on common stock was increased to $0.63 per share, marking the 17th consecutive annual increase.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive report, reflecting successful execution on the growth portfolio and strategic initiatives, but tempered by significant declines in legacy products and a clinical trial discontinuation.

Positives

• Growth Portfolio revenues increased 16% in Q4 to $7.4 billion and 17% for the full year to $26.4 billion, demonstrating strong momentum.
• Key growth drivers include Opdivo, Yervoy, Reblozyl, Breyanzi, Opdualag, Camzyos, Krazati, and Cobenfy, all showing significant revenue increases.
• Eliquis revenues increased 8% worldwide in Q4 to $3.453 billion and 8% for the full year to $14.443 billion.
• The quarterly dividend was increased to $0.63 per share, marking the 17th consecutive annual increase and the 94th consecutive year of dividend payments.
• Camzyos (mavacamten) announced positive topline results from the Phase 3 SCOUT-HCM trial in adolescents, meeting its primary and multiple secondary endpoints with no new safety signals.
• The U.S. FDA granted priority review to the supplemental Biologics License Application for Opdivo in combination for previously untreated Stage III or IV classical Hodgkin Lymphoma, with a PDUFA goal date of April 8, 2026.
• Breyanzi (lisocabtagene maraleucel) received FDA approval as the first and only CAR T treatment for adult patients with relapsed or refractory marginal zone lymphoma.
• The European Commission granted approval to Breyanzi for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.
• An agreement with Microsoft was announced in January 2026, aimed at accelerating early detection of lung cancer through the deployment of FDA-cleared radiology AI algorithms.
• The company achieved its targeted ~$10 billion debt paydown ahead of schedule, strengthening its balance sheet.

Negatives

• Legacy Portfolio revenues decreased 15% in Q4 to $5.1 billion and 15% for the full year to $21.8 billion, primarily due to generic competition.
• Significant revenue declines were observed for Revlimid (down 55% in Q4, 49% full year), Pomalyst/Imnovid (down 16% in Q4, 23% full year), Sprycel (down 60% in Q4, 62% full year), and Abraxane (down 52% in Q4, 58% full year).
• Non-GAAP EPS decreased 25% in Q4 2025 to $1.26 from $1.67 in Q4 2024.
• The decision was made to stop the Phase 3 Librexia ACS trial evaluating milvexian when added to standard of care for patients after a recent acute coronary syndrome event, due to lack of efficacy.
• Acquired IPRD charges were $1.4 billion in Q4 and $3.7 billion for the full year, primarily driven by the acquisition of Orbital Therapeutics in 2025.
• Non-GAAP gross margin decreased from 74.0% to 71.9% in Q4 and from 75.3% to 72.6% for the full year, reflecting a change in product mix.

Risks

• Increasing pricing pressures from market access, pharmaceutical pricing controls, and discounting.
• Market actions taken by private and government payers to manage drug utilization and contain costs.
• Government actions relating to the imposition of new tariffs, trade restrictions, and export regulations.
• The company's ability to retain patent and market exclusivity for certain products.
• Regulatory changes that result in lower prices, lower reimbursement rates, and smaller populations for whom payers will reimburse.
• Changes under the 340B Drug Pricing Program.
• The company's ability to obtain and maintain regulatory approval for its product candidates.
• The possibility of difficulties and delays in product introduction and commercialization.
• Increasing industry competition.
• Potential difficulties, delays, and disruptions in manufacturing, distribution, or sale of products.
• The company's ability to identify potential strategic acquisitions, licensing opportunities, or other beneficial transactions.
• Failure to complete, or delays in completing, collaborations, acquisitions, divestitures, alliances, and other portfolio actions and the failure to achieve anticipated benefits from such transactions and actions.
• Exposure to litigation and/or regulatory actions or investigations.
• The impact of any healthcare reform and legislation or regulatory action in the United States and international markets.
• Increasing market penetration of lower-priced generic products.
• The failure of the company's suppliers, vendors, outsourcing partners, alliance partners, and other third parties to meet their contractual, regulatory, and other obligations.
• The impact of counterfeit or unregistered versions of the company's products and from stolen products.
• Product label changes or other measures that could result in declining sales.
• Safety or efficacy concerns regarding the company's products or any product in the same class as the company's products.
• The risk of cyber-attacks and unauthorized disclosure of trade secrets or other confidential data.
• The company's ability to execute its financial, strategic, and operational plans.
• The company's ability to attract and retain key personnel.
• The impact of the company's significant indebtedness.
• Political and financial instability of international economies and sovereign risk.
• Interest rate and currency exchange rate fluctuations, credit and foreign exchange risk management.
• Risks relating to the use of social media platforms.
• Issuance of new or revised accounting standards.
• Risks relating to public health outbreaks, epidemics, and pandemics.

Future Outlook

Bristol Myers Squibb projects 2026 revenues between $46.0 billion and $47.5 billion, with Non-GAAP EPS in the range of $6.05 to $6.35. This guidance anticipates continued strength in the Growth Portfolio, partially offsetting an expected 12-16% decline in the Legacy Portfolio. The company highlights 2026 as 'data-rich' with multiple pivotal readouts expected in the back half of the year, aiming for industry-leading, sustainable growth into the 2030s and beyond.

Management Comments

• "We made significant progress in 2025, with real momentum in our Growth Portfolio and a strengthened balance sheet that provides the strategic flexibility to continue investing in growth drivers." Christopher Boerner, Ph.D., board chair and chief executive officer.
• "2026 is data-rich, and we are advancing a truly differentiated pipeline with multiple pivotal readouts expected in the back half of the year. Our core business is strong and growing, and we have the potential to achieve industry-leading, sustainable growth into the 2030s and beyond." Christopher Boerner, Ph.D.

Industry Context

StockSavvy.ai notes that Bristol Myers Squibb's performance reflects a common industry challenge: managing patent expirations and generic competition for blockbuster drugs while simultaneously investing heavily in and launching new, innovative therapies. The strong growth in the "Growth Portfolio" (driven by oncology and immunology assets) is critical for offsetting the significant revenue erosion from the "Legacy Portfolio" (e.g., Revlimid, Pomalyst/Imnovid). The strategic collaboration with Microsoft for AI-driven lung cancer detection indicates a broader industry trend towards leveraging technology for early diagnosis and personalized medicine, potentially opening new revenue streams and improving patient outcomes.

Comparison to Industry Standards

• The decline in legacy products like Revlimid (down 55% in Q4) is consistent with the typical impact of generic entry, similar to what other pharmaceutical companies experience post-patent expiry for major drugs.
• The robust growth of new oncology and immunology assets like Breyanzi (up 49% in Q4) and Camzyos (up 59% in Q4) demonstrates successful product launches and market penetration, comparable to the strong initial uptake seen with other innovative therapies from peers like Novartis's Kymriah or Gilead's Yescarta in CAR T-cell therapy, or newer cardiovascular drugs.
• The decision to stop the milvexian Librexia ACS trial due to lack of efficacy, while a setback, is a common occurrence in pharmaceutical R&D, where many late-stage trials do not meet their endpoints, similar to trial failures seen across the industry for various drug candidates.

Stakeholder Impact

• Shareholders: Positive impact from increased dividend and strong growth in new product portfolio, but potential concerns from declining legacy revenues and R&D setbacks.
• Patients: Potential benefits from new drug approvals (Breyanzi, Opdivo priority review) and positive trial results (Camzyos), as well as the Microsoft collaboration for early lung cancer detection.
• Employees: Strategic productivity initiatives mentioned for R&D and SG&A expenses could imply workforce adjustments, though not explicitly stated.
• Customers/Healthcare Providers: Access to new and expanding indications for key drugs like Breyanzi and Opdivo.
• Creditors: Strengthened balance sheet and debt paydown ahead of schedule indicate improved financial health.

Next Steps

• Multiple pivotal readouts are expected in the back half of 2026 for pipeline assets.
• Continued advancement of a differentiated pipeline with potential for industry-leading growth into the 2030s and beyond.
• The FDA Prescription Drug User Fee Act goal date for Opdivo in cHL is April 8, 2026.
• Preparation for the March 6, 2026, PsA PDUFA for Sotyktu is underway.
• Phase 3 data for Sotyktu in SLE and SjD are expected through 2026 and 2027.
• Continued enrollment of additional patients for the Phase 3 ADEPT-2 study of Cobenfy.
• The Librexia STROKE and Librexia AF studies for milvexian continue as planned.
• Deployment of U.S. FDA-cleared radiology AI algorithms via Microsoft's Precision Imaging Network to accelerate early detection of lung cancer.

Key Dates

Recommendation

Bristol Myers Squibb demonstrates a clear strategy to transition from its declining legacy portfolio to a robust growth portfolio, evidenced by strong performance in key new assets and a strengthened balance sheet. However, the significant revenue erosion from patent expirations and the discontinuation of a late-stage trial for milvexian present ongoing headwinds. The 2026 guidance reflects this transitional period, suggesting a 'hold' as the company navigates these shifts, with future performance heavily reliant on successful pipeline execution and new product uptake.

Keywords

Pharmaceuticals, Biotechnology, Drug Development, Oncology, Immunology, Hematology, Cardiovascular, SEC Filing, Financial Results, EPS, Revenue, Pipeline, Dividend, Patent Expiry, Generic Competition, Growth Portfolio, Legacy Portfolio, Bristol Myers Squibb